Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for the treatment of localized low to intermediate risk prostate cancer, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the Stifel 2014 Healthcare Conference. The presentation is scheduled for Tuesday, November 18, 2014 at 3:35 pm EST in New York City.
Help employers find you! Check out all the jobs and post your resume.
